Mitchell Shawnte 4
4 · Olema Pharmaceuticals, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Olema (OLMA) Chief Legal Officer Mitchell Shawnte Receives Award
What Happened
Mitchell Shawnte, Chief Legal Officer of Olema Pharmaceuticals (OLMA), was granted two derivative awards on February 2, 2026 totaling 276,250 option-type shares (220,000 and 56,250). The Form 4 reports an acquisition price of $0.00 and a total reported value of $0 for these awards (i.e., no cash paid at grant). This is an equity award grant (not a sale or open-market purchase).
Key Details
- Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely).
- Grants: 220,000 and 56,250 derivative shares; total = 276,250.
- Price/value reported on Form 4: $0.00 / $0 (derivative awards).
- Shares owned after transaction: Not specified in the filing.
- Vesting/time & performance conditions:
- Footnote 1: 25% of the shares subject to the option vest on Feb 2, 2027, then 1/48 of total shares vest each month thereafter, contingent on continuous service.
- Footnote 2: Performance-based options vest only if stock-price thresholds are met during two performance periods (Feb 2, 2026 – Dec 31, 2029 and Feb 2, 2026 – Dec 31, 2030) based on a consecutive 30-day average closing price and upon Compensation Committee certification and continued service.
- Filing timeliness: Filed two days after the transaction date; no late-filing flag noted.
Context
These entries are derivative option awards rather than open-market purchases or sales; they represent potential future equity subject to time-based and performance-based vesting conditions. No immediate cash changed hands according to the filing, and vesting depends on continued service and, for part of the grant, meeting specified stock-price performance thresholds. Such grants are common for executive compensation and do not by themselves indicate an insider buying or selling shares on the open market.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-02+220,000→ 220,000 totalExercise: $25.65Exp: 2036-02-01→ Common Stock (220,000 underlying) - Award
Performance Stock Options (Right to Buy)
[F2]2026-02-02+56,250→ 56,250 totalExercise: $25.65Exp: 2036-02-01→ Common Stock (56,250 underlying)
Footnotes (2)
- [F1]25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
- [F2]The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.